

Dedicated to you

Financial Statements

**Ceylon Hospitals PLC** 

For the 3rd Quarter ended 31st December 2021

Consolidated Statement of Profit or Loss and Other Comprehensive Income					Accumulated Period of 9 Months			
	Group Company				Group Company			
	03 Months	03 Months	03 Months	03 Months	9 Months	9 Months	9 Months	9 Months
	Ended	Ended	Ended	Ended	Ended	Ended	Ended	Ended
	31/12/2021	31/12/2020	31/12/2021		31/12/2021	31/12/2020	31/12/2021	31/12/2020
	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000	Rs. '000
Revenue	1,834,290	1,427,401	1,212,531	978,494	5,814,828	3,779,524	3,902,302	2,408,183
Cost of Sales	(632,769)	(483,362)	(404,696)	(322,009)	(2,110,634)	(1,281,091)	(1,475,777)	(802,158)
Gross Profit	1,201,521	944,038	807,835	656,485	3,704,195	2,498,433	2,426,525	1,606,025
Other Operating Income	19,235	6,725	10,736	4,370	43,716	25,715	27,045	18,665
Administrative Expenses	(648,754)	(566,843)	(429,650)	(378,925)	(2,158,958)	(1,632,281)	(1,534,024)	(1,090,878)
Other Operating Expenses	(197,079)	(141,171)	(111,061)	(94,805)	(531,473)	(395,749)	(337,092)	(250,491)
Results from Operating Activities	374,924	242,750	277,860	187,126	1,057,480	496,119	582,454	283,321
Finance Cost	(19,092)	(12,335)	(16,811)	(10,678)	(59,560)	(74,803)	(56,058)	(67,748)
Finance Income	20,401	11,439	1,802	654	55,387	33,263	248,496	208,804
Gain on Bargain Purchase	-	-	-	-	12,002		-	
Share of Profit of an Equity Accounted Investee		50,105	-	-	13,263	54,767	-	-
Profit before Taxation	376,233	291,959	262,852	177,102	1,078,571	509,346	774,893	424,377
Taxation	(55,320)	(27,630)	(28,863)	(15,894)	(233,876)	(69,336)	(117,519)	(23,794)
Net Profit after Taxation	320,913	264,330	233,988	161,208	844,695	440,010	657,374	400,584
Other Comprehensive Income Items will not be reclassified to profit or loss Net Change in Fair Value on Equity Investments at								
FVOCI	2,104	(959)	2,104	(164)	2,168	2,519	2,168	244
Other Comprehensive Income for the Year	2,104	(959)	2,104	(164)	2,168	2,519	2,168	244
Total Comprehensive Income for the Year	323,017	263,370	236,092	161,044	846,863	442,529	659,542	400,828
Profit Attributable to:								
Equity Holders of the Parent	318,852	256,672	233,988	161,208	756,831	411,013	657,374	400,584
Non-Controlling Interest	2,061	7,657	-	-	87,864	28,997	-	-
	320,913	264,330	233,988	161,208	844,695	440,010	657,374	400,584
Total Comprehensive Income Attributable to:								
Equity Holders of the Parent	320,956	256,019	236,092	161,044	758,999	413,260	659,542	400,828
Non-Controlling Interest	2,061	7,351	-	-	87,864	29,269	-	
	323,017	263,370	236,092	161,044	846,863	442,529	659,542	400,828
Earnings per Share - Basic	9.41	7.58	6.91	4.76	22.34	12.13	19.41	11.83

The above figures are provisional and subject to audit.

Ceylon Hospitals PLC

## **Consolidated Statement of Financial Position**

GROUP	COMPANY		GRO	UP	COMP	ANY
Audited	Audited		Unaudited	Unaudited	Unaudited	Unaudited
As at	As at		As at	As at	As at	As at
31/03/2021	31/03/2021		31/12/2021	31/12/2020	31/12/2021	31/12/2020
Rs. '000	Rs. '000		Rs. '000	Rs. '000	Rs. '000	Rs. '000
		ASSETS				
		Non-Current Assets				
7,714,638	5,083,367	Property, Plant and Equipment	8,190,051	7,681,701	5,417,958	5,042,419
214,544		Right of Use Assets	293,283	206,402	293,283	206,402
-		Investments in Subsidiary	-	-	1,457,821	1,457,591
109,374		Investment in Equity Accounted Investee	-	60,264	-	230
165,973	66,910	Other Financial Assets	343,835	115,189	71,267	65,722
990	-	_Prepaid Rent	579	1,015		-
8,205,519	6,822,642	_	8,827,748	8,064,572	7,240,329	6,772,365
		Current Assets				
535,877	450,475	Inventories	679,882	461,285	553,293	361,028
237,950		Trade and Other Receivables	331,578	351,405	180,385	249,978
155,456		Prepayments	240,561	166,163	179,841	139,939
2,418		Amount Due from Related Parties	4,036	87,192	111,931	456,397
1,106,141		Other Financial Assets	958,820	707,326	149,524	88,030
-	-	Tax Refund Due	-	25,165	-	-
640,115	225,211	Cash and Cash Equivalents	772,382	316,541	129,181	71,382
2,677,958	1,160,034	-	2,987,258	2,115,077	1,304,155	1,366,754
10,883,477	7,982,676	Total Assets	11,815,006	10,179,649	8,544,484	8,139,119
'		EQUITY AND LIABILITIES				
		Equity Attributable to Equity holders of the parent				
916,366	916.366	Stated Capital	916,366	916,366	916,366	916,366
2,691,662		Revaluation Reserve	2,691,662	2,483,785	2,134,544	1,931,063
68,436		Fair Value Reserve	70,604	68,169	2,296	244
2,951,439		Revenue Reserves	3,599,877	2,776,246	2,535,381	1,914,128
6,627,903	5,037,438	_	7,278,509	6,244,566	5,588,587	4,761,801
592,626	-	Non-Controlling Interests	693,439	580,920	-	-
7,220,530	5,037,438	Total Equity	7,971,948	6,825,486	5,588,587	4,761,801
		N. G. (XIII)				
022.144	704 444	Non-Current Liabilities	1.042.66	(0.010	037.004	572.010
823,144		Interest Bearing Loans and Borrowings	1,043,665	606,910	936,891	573,010
-	,	Deferred Revenue	-	-	32,254	33,708
242,882		Retirement Benefit Obligations	243,888	266,333	218,177	236,248
642,694 1,708,719		_ Deferred Tax Liabilities	652,562	918,348	440,809	699,797
1,/08,/19	1,475,592		1,940,116	1,791,590	1,628,131	1,542,763
221 727	72 904	Current Liabilities Bank Overdraft	101 775	342,838	92,213	104 297
221,737		Interest Bearing Loans and Borrowings	181,775 336,426			104,387
829,176 671,130		Trade and Other Payables	336,426 1,243,629	659,694 536,258	279,255 796,223	610,194 275,787
55,191		Taxation Payable	1,243,629	3,669	66,615	733
176,994		Amount Due to Related Parties	12,064	20,113	93,460	843,452
1,954,228	1,469,647		1,902,942	1,562,573	1,327,765	1,834,555
10,883,477		Total Equity and Liabilities	11,815,006	10,179,649	8,544,484	8,139,119
10,003,777	1,702,070		11,012,000	10,177,077	0,077,707	0,137,117

The above figures are provisional and subject to audit.

Snd.

R K Thusitha

Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements. Signed for and on behalf of the Board by,

Snd. Snd. A E Tudawe

U D Tudawe Chairman Director

10th February 2022

# CEYLON HOSPITALS PLC STATEMENT OF CHANGES IN EQUITY

Group	Stated Capital	Revaluation Reserve	Fair Value Reserve	Accumulated Profits	Total	Non-Controlling Interest	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
Balance as at 31st March 2020	916,366	2,483,785	65,922	2,439,753	5,905,826	587,760	6,493,586
Net Profit for the Period	-	=	=	560,349	560,349	39,910	600,259
Other Comprehensive Income							
Deferred Tax Effect on Revaluation Gain	-	207,877	-	-	207,877	752	208,629
Actuarial Gain on Gratuity Valuation	-	-	-	32,865	32,865	370	33,235
Deferred Tax Charge on actuarial Loss on Gratuity Valuation	-	-	-	(7,007)	(7,007)	(610)	(7,618)
Net Change in Fair Value on Equity Investments at FVOCI	-	-	2,514	-	2,514	554	3,068
<b>Total Comprehensive Income for the Period</b>	-	207,877	2,514	586,206	796,597	40,975	837,572
Transactions with Owners in their capacity as Owners							
Share of additional capital attributable to NCI	-	-	-	-	-	1,750	1,750
Dividend Paid - Ordinary Shares	-	-	-	(74,520)	(74,520)	(37,859)	(112,379)
	-	-	-	(74,520)	(74,520)	(36,109)	(110,629)
Balance as at 31st March 2021	916,366	2,691,662	68,436	2,951,439	6,627,903	592,626	7,220,530
Net Profit for the Period	-	-	=	756,831	756,831	87,864	844,695
Other Comprehensive Income							
-Value through other comprehensive income	-	-	2,168	-	2,168	-	2,168
<b>Total Comprehensive Income for the Period</b>	-	-	2,168	756,831	758,999	87,864	846,863
Transactions with Owners in their capacity as Owners							
Non-Controlling Interest on Acquisition of Subsidiary	-	-	-	-	-	126,444	126,444
Dividend Paid - Ordinary Shares	-	-	-	(108,393)	(108,393)	(113,496)	(221,888)
	-	-	-	(108,393)	(108,393)	12,948	(95,444)
Balance as at 31st December 2021	916,366	2,691,662	70,604	3,599,877	7,278,509	693,439	7,971,948

## Company

	Stated Capital Rs.	Revaluation Reserve Rs.	Fair Value Reserve Rs.	Accumulated Profits Rs.	Total Rs.
Balance as at 31st March 2020	916,366	1,931,063	-	1,588,064	4,435,493
Net Profit for the Period	-	-	-	446,118	446,118
Other Comprehensive Income					
Deferred Tax Effect on Revaluation Gain	-	203,481	-	-	203,481
Actuarial Gain on Gratuity Valuation	-	-	-	31,090	31,090
Deferred Tax Effect on Gratuity Valuation	-	-	-	(4,353)	(4,353)
Net Change in Fair Value on Equity Investments at FVOCI	-	-	128.00	=	128
<b>Total Comprehensive Income for the Period</b>	-	203,481	128	472,855	676,464
Transactions with Owners in their capacity as Owners Dividend Paid - Ordinary Shares	-	-	-	(74,520) (74,520)	(74,520) (74,520)
_				(74,320)	(74,320)
Balance as at 31st March 2021	916,366	2,134,544	128	1,986,400	5,037,438
Net Profit for the period	-	-	-	657,374	657,374
Other Comprehensive Income Net Profit on equity instruments designnated at fair-					-
-Value through other comprehensive income	-	-	2,168	-	2,168
<b>Total Comprehensive Income for the Period</b>	-	-	2,168	657,374	659,542
<b>Transactions with Owners in their capacity as Owners</b> Dividend Paid - Ordinary Shares	-	_	-	(108,393)	(108,393)
· -	-	-	-	(108,393)	(108,393)
Balance as at 31st December 2021	916,366	2,134,544	2,296	2,535,381	5,588,587

# Consolidated Statement of Changes in Equity For the period ended 31st December 2020

Group
-------

	Stated Capital	Revaluation Reserve	Fair Value Reserve	Revenue Reserves	Total	NCI	Total
	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
Balance as at 31st March 2019	916,366	1,986,853	69,939	2,169,904	5,143,062	564,744	5,707,805
Net Profit for the Year	-	-	-	403,274	403,274	63,819	467,093
Other Comprehensive Income							
Deferred Tax Effect on Revaluation Gain	-	(186,990)	-	-	(186,990)	(4,091)	(191,080)
Deferred Tax Effect on Gratuity valuation	-	-	-	4,149	4,149	98	4,247
Net Gain/ (Loss) on Gratuity valuation	-	-	-	(15,632)	(15,632)	(490)	(16,122)
Net Gain/ (Loss) on Land and Building valuation	-	683,922	-	-	683,922	26,413	710,335
Net Change in Fair Value on Equity Investments at FVOCI	-	-	(4,017)	-	(4,017)	(920)	(4,937)
<b>Total Comprehensive Income for the Year</b>	-	496,933	(4,017)	391,791	884,706	84,830	969,536
Transactions with Owners in their capacity as Owners							
Dividend Paid - Ordinary Shares	-	-	-	(121,942)	(121,942)	(61,814)	(183,756)
		-	-	(121,942)	(121,942)	(61,814)	(183,756)
Balance as at 31st March 2020	916,366	2,483,785	65,922	2,439,753	5,905,826	587,760	6,493,586
Net Profit for the Period	-	-	-	411,013	411,013	28,997	440,010
Other Comprehensive Income							
Net Change in Fair Value on Equity Investments at FVOCI		-	2,247	-	2,247	272	2,519
<b>Total Comprehensive Income for the Period</b>	-	-	2,247	411,013	413,260	29,269	442,529
Transactions with Owners in their capacity as Owners							
Non-Controlling Interest on Acquisition of Subsidiay	-	-	-	-	-	1,750	1,750
Dividend Paid - Ordinary Shares	-	-	-	(74,520)	(74,520)	(37,859)	(112,379)
·	-		-	(74,520)	(74,520)	(36,109)	(110,629)
Balance as at 31st December 2020	916,366	2,483,785	68,169	2,776,246	6,244,566	580,920	6,825,486

## Company

	Stated Capital Rs.	Revaluation Reserve Rs.	Fair Value Reserve Rs.	Revenue Reserves Rs.	Total Rs.
Balance as at 31st March 2019	916,366	1,564,589	56	1,502,005	3,983,016
Net Profit for the Year	-	-	-	217,404	217,404
Other Comprehensive Income					
Deferred Tax Effect on Revaluation Gain	-	(163,081)	-	-	(163,081)
Deferred Tax Effect on Gratuity valuation	_	-	-	3,657	3,657
Net Gain/ (Loss) on Gratuity valuation	-	-	-	(13,060)	(13,060)
Net Gain/ (Loss) on Land and Building valuation	_	529,555	_	-	529,555
Net Change in Fair Value on Equity Investments at FVOCI	-	-	(56)	-	(56)
<b>Total Comprehensive Income for the Year</b>	-	366,474	(56)	208,001	574,419
Transactions with Owners in their capacity as Owners Dividend Paid - Ordinary Shares	_	_	_	(121,942)	(121,942)
	-	-	-	(121,942)	(121,942)
Balance as at 31st March 2020	916,366	1,931,063		1,588,064	4,435,493
Net Profit/(Loss) for the period	-	-	-	400,584	400,584
Other Comprehensive Income					
Net Change in Fair Value on Equity Investments at FVOCI	_	_	244	_	244
Total Comprehensive Income for the Period	-	-	244	400,584	400,828
Transactions with Owners in their capacity as Owners					
Dividend Paid - Ordinary Shares	_	_	_	(74,520)	(74,520)
	-	-	-	(74,520)	(74,520)
Balance as at 31st December 2020	916,366	1,931,063	244	1,914,128	4,761,801

Ceylon Hospitals PLC

# **Statement of Cash Flows**

Group	Company		Gro	un	Compa	anv
Audited	Audited		Unaudited	Unaudited	Unaudited	Unaudited
12 Months	12 Months		9 Months	9 Months	9 Months	9 Months
Ended	Ended		Ended	Ended	Ended	Ended
31/03/2021	31/03/2021		31/12/2021	31/12/2020	31/12/2021	31/12/2020
Rs '000	Rs '000		Rs '000	Rs '000	Rs '000	Rs '000
(0,(,220	452 622	Cash Flows from/ (Used in) Operating Activities	1 070 571	500 246	77.4.002	404 277
696,339	453,632	Net Profit Before Income Tax Expenses	1,078,571	509,346	774,893	424,377
		Adjustments for:				
6,705	5 550	Inventory Write-off/(Net)	23,533	2,624	18,732	2,588
		Bad Debts Write-off	· · · · · · · · · · · · · · · · · · ·			
11,335 354,740			1,114	6,529	1,101 136,687	771 146,182
		Depreciation Charge for the Year	248,770	278,381 74,039	/	
101,892		Amortisation of Right to use assets	79,201		79,201	74,039
(50,308)		Finance Income	(55,387)	(33,263)	(248,496)	(208,804)
96,679		Finance Cost	59,560	74,803	56,058	67,748
100		Amortisation of Deferred Rent	411	75	(1,007)	(1,343)
(5,340)		(Profit)/ Loss on Disposal of Property, Plant and Equipment		(1,694)	•	(1,694)
5,412		(Increase)/ Decrease in Financial Instruments	3,659	2,519	2,168	244
(102,871)	-	Share of Profit of an Equity Accounted Investee	(13,263)	(54,767)	-	-
49,845		Provision for Defined Benefit Plans	29,390	29,000	24,300	23,600
1,164,528	662,809	Operating Profit before Working Capital Changes	1,455,559	887,593	843,636	527,709
(162,833)	(147 103)	(Increase)/Decrease in Inventories	(167,538)	(84,159)	(121,551)	(54,694)
80,106		(Increase)/Decrease in Trade and Other Receivables	(179,847)	(39,249)	(82,923)	(66,608)
160,669		Increase/(Decrease) in Trade and Other Payables	572,499	7,741	411,507	(34,538)
219,127		(Increase)/Decrease Related Party Dues	(166,549)	(22,529)	(112,429)	(31,585)
1,461,598		Cash Generated from Operations	1,514,126	749,397	938,240	340,284
1,401,598	323,001	Cash deherated from Operations	1,514,120	149,391	930,240	340,264
(70,135)	(61,624)	Finance Cost Paid	(49,029)	(56,747)	(45,527)	(49,692)
(39,020)	(30,438)	Defined Benefit Plan Costs Paid	(28,383)	(27,959)	(23,201)	(22,455)
(87,932)	(15,946)	Income Tax Paid	(150,150)	(63,231)	(92,798)	(13,527)
1,264,511	217,593	Net Cash from Operating Activities	1,286,563	601,460	776,715	254,610
		Cook Elema from (cook in) Immedia a Astinition				
(204.556)	(200, 170)	Cash Flows from/ (used in) Investing Activities	(52( 222)	(225 907)	(452,020)	(264,000)
(384,556)		Acquisition of Property, Plant and Equipment	(726,223)	(325,807)	(473,028)	(264,890)
(2,425)		Acquisition of Right to use assets	(4,012)	(7,242)	(4,012)	(7,242)
13,945		Proceeds from Sale of Property, Plant and Equipment	2,040	1,290	1,750	1,000
(444,441)		(Acquisition)/ Disposal of other Investments	90,605	8,508	(30,705)	(3,824)
50,308		Income from Investments	55,387	33,263	248,496	208,804
(767,169)	(111,558)	Net Cash Flows from/ (used in) Investing Activities	(582,203)	(289,989)	(257,499)	(66,153)
		Cash Flows from/ (used in) Financing Activities				
915,630	890.630	Receipts from Interest Bearing Loans and Borrowings	318,329	473,588	200,909	448,588
(302,106)		Re-payments to Interest Bearing Loans and Borrowing	(658,918)	(139,340)	(630,983)	(128,940)
(116,569)		Lease Rent Payment	(96,098)		(96,098)	(96,098)
1,750	(110,507)	Proceeds from the Issue of Shares	(20,020)	1,750	(>0,0>0)	(70,070)
1,730		Non-Controlling Interest on Acquisition of Subsidiary	126,444	1,730	-	
(112,379)	(74.520)	Dividends Paid	(221,888)	(112,379)	(108,393)	(74,520)
386,326		Net Cash Flows from/ (used in) Financing Activities	(532,131)	127,521	(634,565)	149,030
300,320	410,773	The Cash Flows from (used in) I maneing Activities	(332,131)	127,321	(034,303)	147,030
883,668	522,810	Net Increase/ (Decrease) in Cash and Cash Equivalents	172,228	438,993	(115,349)	337,488
(465,289)		Cash and Cash Equivalents at the Beginning of the Year	418,379	(465,289)	152,317	(370,493)
418,379	152,317	Cash and Cash Equivalents at the End of the Year	590,607	(26,296)	36,967	(33,005)
		Analysis of Cash and Cash Equivalents				
(221,737)	(72,894)	Bank Overdraft	(181,775)	(342,838)	(92,213)	(104,387)
640,115	225,211	Cash in Hand and at Bank	772,382	316,541	129,181	71,382
418,379	152,317		590,607	(26,296)	36,967	(33,005)

#### **Explanatory Notes**

#### 01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

#### 02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the period ended 31 December 2021, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein

#### 03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the period ended 31 December 2021 were authorised for issue by the Board of Directors on 10 February 2022.

#### 04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

#### 4.1 Basis of preparation

The interim financial statements for the period ended 31 December 2021 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements as at 31 March 2021.

#### 4.2 Fair value measurement and related fair value disclosures

The fair values of all the financial assets and financial liabilities recognised during the quarter were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Fair valuation was done as of 31 December 2021 for all unquoted equity shares classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed.

#### 4.3 COVID - 19 impact assessment

The Company has been in continuous operation although at reduced level subject to guidelines set out by the Government of Sri Lanka (GOSL) during the COVID-19 pandemic confirming to the regulations and guidelines issued by the GOSL. Ministry of Health (MOH) and other allied authorities.

Although it is too early to make an assessment, the Company has seen a smooth transition with the resumption of business activities with a positive momentum. Given the volatile and evolving landscape, the Company will continue to monitor the impacts on it's operations and proactively take measures to ensure the business continues as seamlessly as possible.

No circumstances have arisen since the Balance Sheet date, which would require adjustment or disclosure in the interim Financial Statements other than what is stated above.

- 05. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements.
- 06. Related party transactions for the quarter ended 31 December 2021 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

#### Ceylon Hospitals PLC

#### **Related Party Transactions** For the period ended 31 December 2021 In LKR '000s

			ı
Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Ultimate Parent	Management fee Rendering of utilities and other cost	Recurrent Recurrent	38,660
	Total		38,660
Subsidiary	Sales of Drugs and consumables	Recurrent	24,931 230,858
	Rendering of utilities and other cost	Recurrent	289,252
	Receiving of medical services	Recurrent	22,573 438,792
	Receiving of utilities and other cost  Total	Recurrent	28,954 1,035,360
Subsidiary	Sales of Drugs and consumables Rendering of medical services Rendering of utilities and other cost Purchases of Drugs and consumables	Recurrent Recurrent Recurrent Recurrent	2,344 82,953 52,706 6,714
	Receiving of medical services Receiving of utilities and other cost Total	Recurrent Recurrent	61,709 6,422 <b>212,848</b>
Subsidiary	Rendering of utilities and other cost  Total	Recurrent	1,507 <b>1,507</b>
Subsidiary	Purchases of Drugs and consumables Receiving of utilities and other cost Total	Recurrent Recurrent	284,279 4,731 <b>289,010</b>
Affiliate	Purchases of Drugs and consumables Receiving of utilities and other cost Total	Recurrent Recurrent	85,322 16 85,338
Affiliate	Rendering of medical services  Total	Recurrent	1,247 <b>1,247</b>
Relationship	Transactions	Nature	Aggregate Value of Related Party Transactions
Affiliate	Project 2022 Construction Cost Total	Non Recurrent	115,966 <b>115,966</b>
	Ultimate Parent  Subsidiary  Subsidiary  Subsidiary  Affiliate  Affiliate  Relationship	Ultimate Parent Rendering of utilities and other cost Total  Subsidiary Sales of Drugs and consumables Rendering of medical services Rendering of utilities and other cost Purchases of Drugs and consumables Receiving of medical services Receiving of utilities and other cost Total  Subsidiary Sales of Drugs and consumables Rendering of medical services Rendering of tutilities and other cost Purchases of Drugs and consumables Receiving of utilities and other cost Purchases of Drugs and consumables Receiving of utilities and other cost Total  Subsidiary Rendering of utilities and other cost Total  Affiliate Purchases of Drugs and consumables Receiving of utilities and other cost Total  Affiliate Purchases of Drugs and consumables Receiving of utilities and other cost Total  Affiliate Purchases of Drugs and consumables Receiving of utilities and other cost Total  Affiliate Purchases of Drugs and consumables Receiving of utilities and other cost Total  Total  Affiliate Purchases of Drugs and consumables Receiving of utilities and other cost Total  Total  Purchases of Drugs and consumables Receiving of utilities and other cost Total  Purchases of Drugs and consumables Receiving of utilities and other cost Total  Purchases of Drugs and consumables Receiving of utilities and other cost Total	Ultimate Parent Rendering of utilities and other cost Recurrent Recurrent  Subsidiary Sales of Drugs and consumables Rendering of medical services Rendering of medical services Recurrent Recurrent Recurrent Receiving of medical services Recurrent Receiving of medical services Recurrent Receiving of medical services Recurrent Receiving of utilities and other cost Recurrent Receiving of utilities and other cost Recurrent Recurrent Rendering of utilities and other cost Recurrent Rendering of medical services Rendering of utilities and other cost Recurrent Recurrent Receiving of medical services Recurrent Recurrent Receiving of medical services Recurrent Recurrent Receiving of medical services Receiving of utilities and other cost Recurrent Recurrent Receiving of utilities and other cost Recurrent Recurrent Receiving of utilities and other cost Recurrent Total  Subsidiary Rendering of utilities and other cost Recurrent Recurrent Receiving of utilities and other cost Recurrent Recurrent Receiving of utilities and other cost Recurrent Recurrent Total  Affiliate Purchases of Drugs and consumables Recurrent

#### **Share Information**

# **Number of Shares Represented in Stated Capital**

Voting Shares	25,527,272
Non-Voting Shares	8,345,454
Total	33,872,726

# Public Shareholding as at 31 December 2021

	Voting	Non-Voting	
Number of shareholders	2,239	1,238	
Number of shares	6,030,824	4,284,128	
Holding Percentage	23.63%	51.33%	
Float Adjusted Market Capitalisation (Rs Mn)	911		
Float Adjusted Market Capitalisation Option	Less than 2.5 Bn (Option 5)		

# Director's and Chief Executive Officer's Shareholding as at 31 December 2021

	Number of Shares		
	Voting	Non-Voting	
Mr A E Tudawe	215,052	-	
Mr U D Tudawe	170,616	-	
Dr A D P A Wijegoonewardene	220,582	-	
Mr Y N R Piyasena	501,000	-	
Mr A S Abeyewardene	1,440	1,200	
Mr A S M Ismail	100	-	
Mr A D B Talwatte	1,000	-	
Mr. A.V.R. De Silva Jayatilleke	100	-	
Mr. A.S. Tudawe	48	1,000	

## Market Prices recorded during the Quarter

Hig	ghest	Lov	vest	L	ast
Trade	d Price	Trade	d Price	Trade	ed Price
2021/22	2020/21	2021/22	2020/21	2021/22	2020/21
Rs	Rs	Rs	Rs	Rs	Rs
152.00	114.80	119.50	82.60	151.00	103.20
31/12/2021	09/11/2020	01/10/2021	23/10/2020	31/12/2021	31/12/2020
130.00 27/12/2021	102.00 08/12/2020	103.00 18/10/2021	80.00 <i>08/10/2020</i>	123.50 31/12/2021	90.00 28/12/2020
	Trade 2021/22 Rs 152.00 31/12/2021	Rs Rs  152.00 114.80 31/12/2021 09/11/2020  130.00 102.00	Traded Price         Trade           2021/22         2020/21         2021/22           Rs         Rs         Rs           152.00         114.80         119.50           31/12/2021         09/11/2020         01/10/2021           130.00         102.00         103.00	Traded Price         Traded Price           2021/22         2020/21         2021/22         2020/21           Rs         Rs         Rs         Rs           152.00         114.80         119.50         82.60           31/12/2021         09/11/2020         01/10/2021         23/10/2020           130.00         102.00         103.00         80.00	Traded Price         Trade Price

# **Per Share Ratios**

	Gre	Group		Company	
	As at 31/12/2021 Rs	As at 31/12/2020 Rs	As at 31/12/2021 Rs	As at 31/12/2020 Rs	
Earnings Per Share	22.34	12.13	19.41	11.83	
Net Asset Per Share	214.88	184.35	164.99	140.58	

# Top 20 Shareholders Listed as at 31 December 2021

# **Voting Shareholders**

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	17,456,507	68.38
Lawrance Tudawe Management Services (Pvt) Ltd	do	600,077	2.35
Mr Y N R Piyasena	do	501,000	1.96
Mr Deen Mohamed Fazal Aslam	do	453,000	1.77
Guardian Capital Partners PLC	do	400,000	1.57
Mr Merill J Fernando	do	367,530	1.44
Mr S P Tudawe (Deceased)	do	307,936	1.21
Cargo Boat Development Company PLC	do	305,485	1.20
MJF Holdings Ltd	do	270,981	1.06
Mr DG Wijemanna	do	240,831	0.94
Mr A D P A Wijegoonewardene	do	220,582	0.86
Mr R P Weerasooriya	do	215,080	0.84
Mr A E Tudawe	do	215,052	0.84
Mrs H K Weerasinghe	do	200,000	0.78
Mrs L I Weerasinghe	do	200,000	0.78
Mrs T T Weerasinghe	do	200,000	0.78
Mr U D Tudawe	do	170,616	0.67
Mr A D Tudawe	do	161,984	0.63
Mr R R Tudawe	do	100,000	0.39
Mr A H Munasinghe	do	91,326	0.36
		22,677,987	88.84

# **Non-Voting Shareholders**

Name of the Shareholder	Country of Residence	Number of Shares	Holding %
Durdans Management Services Ltd	Sri Lanka	2,664,751	31.93
Employee Provident Fund	do	1,154,371	13.83
MJF Holdings Ltd	do	598,646	7.17
E W Balasuriya & Co (Pvt) Ltd	do	330,619	3.96
Mr D Ratnayake	do	146,866	1.76
Mr A H Munasinghe	do	143,614	1.72
Tudawe Engineering Services (Pvt) Ltd	do	91,986	1.10
Mr D A Cabraal	do	82,500	0.99
Mr S S Sithambaranathan	do	77,753	0.93
Mr P S De Mel	do	70,822	0.85
Mr A D Tudawe	do	70,151	0.84
Ms T T Weerasinghe	do	68,485	0.82
Peoples Leasing & Finance PLC /Mr P A I S Perera	do	65,454	0.78
Commercial Bank of Ceylon PLC A/C No 04	do	61,100	0.73
Mr U D Wickremesooriya Jt Mrs S F Wickremesooriya	do	59,272	0.71
Mr DP L De Mel	do	58,908	0.71
Saman Villas Limited	do	58,462	0.70
Mr H A Cabraal	do	50,000	0.60
Hallsville Trading Group Inc	do	49,123	0.59
DR DBK De Silva	do	47,612	0.57
	•	5,950,495	71.30

#### CORPORATE INFORMATION

# Name of Company

Ceylon Hospitals PLC

## **Brand Name**

**DURDANS** 

## **Legal Form**

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

## **Company Registration Number**

PQ 113

## **Stocks Exchange Listing**

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

## **Registered Office**

No.03, Alfred Place, Colombo 03.

## **Bankers**

Bank of Ceylon Commercial Bank of Ceylon PLC DFCC Bank PLC Hatton National Bank PLC National Development Bank PLC Nations Trust Bank PLC Sampath Bank PLC Seylan Bank PLC Union Bank PLC People's Bank

## **Auditors**

Messers.B.R.De.Silva & Co. Chartered Accountants No.22/4,Vijaya Kumaratunga Mawatha Colombo 05.

# **Ceylon Hospitals PLC**

Lawyers

Mr.D.F.R.Jayamaha Hector Jayamaha Law Office, No.228,Thimbirigasyaya Road, Colombo 05.

#### Secretaries

Nexia Corporate Consultants (Pvt) Ltd No 181, Nawala road, Narahenpita.

## Registrars

S S P Corporate Services (Pvt) Ltd 546, Galle Road, Colombo 03.